Search results for query: sensorion

Positive Phase 2a results, with clinically meaningful hearing preservation at 250, 500 & 750 Hz compared to controls. → Sensorion Announces Positive Results from Phase 2a Clinical Trial of SENS-401 in Cochlear Implantation

Not to be impatient but is the staff still planning to share some news about this?

Sensorion Announces its Participation in the Association for Research in Otolaryngology ARO 47th Annual Midwinter Meeting I am particularly interested in whether Sensorion SA has any plans of testing SENS-111 (an histamine receptor 4 antagonist) for the treatment of tinnitus. Sensorion filed...

It's curious how the questions around tinnitus have changed -- which by the way is maybe a sign of progress of sorts. Instead of "does this new pharma/method cure or alleviate tinnitus", the question seems to have moved more in the direction of "what sort of tinnitus do you have... and maybe...

Hey! Sorry for the late response. That's an intriguing story re SENS-111. Unfortunately, for all of us, what happened to the drug will remain a mystery. As you noted, even though the company did two talks and three poster presentations, SENS-111 is not mentioned in any of them. If we had...

They only reported on the presence of drug, not hearing changes vs. control at this stage: → Sensorion Announces it Has Met Primary Endpoint for SENS-401 Phase 2a Clinical Study for Residual Hearing Preservation

Sensorion SA filed a patent for H4 receptor inhibitors to treat tinnitus. Pimozide doesn't seem to be included in their list of compounds from which Sensorion SA will select their H4R inhibitor. I also have found no evidence that Pimozide is a H4 antagonist. It is included in a list of H4...

Hi, I had never heard much about this company before. → Sensorion, the Specialist in Inner Ear Diseases, Completes a New Funding Round to Begin the Human Clinical Trial Phase

...the company says its SENS-111 was safe and well tolerated by trial participants, it did not meet the primary endpoint of vertigo intensity." I wonder if SENS-111 as a tinnitus treatment is still on Sensorion's table. They filed a patent for H4 receptor inhibitors to treat tinnitus in 2018.

Is this the fault of Sensorion?

All these trials are failing left, right and center. It's a shame.

Sensorion Update on SENS-401 Update from 17 March 2022. To be honest I am really confused why they failed with drug when there was a minimum of 10 dB improvement in 28 days as well as other bigger improvements in sub-groups. Can someone explain me please, isn't a 10 dB improvement a lot when...

Sensorion Reports Positive Efficacy Data from SENS-401 Phase 2a Clinical Study Positive preliminary data showed SENS-401 has a clinically significant effect on the preservation of residual hearing after cochlear implantation in all adult patients treated so far On the 19th of June, Sensorion...

Sensorion Receives FDA IND Approval for Arazasetron (SENS-401) https://finance.yahoo.com/news/sensorion-receives-fda-ind-approval-053000700.html

This is an update from todays presentation http://m.4-traders.com/SENSORION-21685779/news/Sensorion-Presents-New-SENS-401-Data-at-ARO-2018-MidWinter-Meeting-25988660/

Without knowing a lot about this drug, I believe that a 10 dB change doesn't mean anything much, since it may be due to testing errors. There is a whole range of subjective stuff that can happen within 10 dB. I personally have audiograms that show that one time I lost 10 dB at some frequency and...

@Zugzug, there are also the Sensorion drugs to add, potentially, as from this thread.

...drug candidate. Separately SENS-401 demonstrated in preclinical testing to have a preventive effect against cisplatin-induced ototoxicity. Sensorion subsequently received Orphan Drug Designation for SENS-401 by the FDA in this indication in a pediatric population and confirmed its objective...

https://finance.yahoo.com/news/sensorion-provides-sens-401-ssnhl-063000237.html Delays in recruitment as a result of COVID-19. Wonder how this sort of thing bodes for the likes of Frequency...

...Ear Disorders Therapeutics Summit Participants include Acousia Therapeutics, Akouous, Spiral Therapeutics, Astellas, Ting Therapeutics, Sensorion and AudioCure Pharma. Seems a lot of early stage, pre-clinical companies attending. I will report if some more information or summaries become...

Interesting: http://www.businesswire.com/news/home/20160222005808/en/Sensorion-Presents-SENS-218-Data-Association-Research-Otolaryngology

This is really exciting news. This is a new H4 receptor antagonist aimed at treating tinnitus going to clinical trials. The active substance is called SENS-111: Then they have another one called SENS-218: (Source)

And a small update: http://www.businesswire.com/news/home/20161116006407/en/Sensorion-Presents-Preclinical-Results-SENS-401-Acute-Sensorineural

Hello, I am trying to inform you about the latest results from Sensorion for their treatment called: "SENS-401" I'm French, and I found an English link, so I'm coming to post it to give you some good news. Sorry if my english is sad, I translate it with internet...

Collaboration between Sensorion and Cochlear to attempt to improve outcomes for Cochlear Implant patients: http://www.sensorion-pharma.com/images/press-release/20171218_PR_SensorionCochlear_18122017_1_EN.pdf

Sensorion announces €5.6m non-dilutive funding to support SENS-401 Phase 2 study in Sudden Sensorineural Hearing Loss French ministry of armed forces to participate in the study https://www.sensorion-pharma.com/images/press-release/20191223-PR-SENS401-PATRIOT-PSPC.pdf Good news I guess even if...

A couple of poster presentations at the ARO Midwinter meetings on SENS-401: https://www.businesswire.com/news/home/20180124005881/en/Sensorion-Announces-Multiple-Poster-Presentations-ARO-2018

@JohnAdams Do you know of other companies that are currently doing clinical trials to cure tinnitus? The only ones I know that are currently doing trials are Frequency Therapeutics, Decibel Therapeutics and Sensorion?

Sensorion (ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biopharmaceutical company which specializes in the development of novel therapies to restore, treat and prevent inner ear diseases such as hearing loss, tinnitus and vertigo, today announced that the independent Data Safety...

Sensorion just announced a COVID-19 related delay in their trial. Unfortunately, i imagine other biotechs doing the same very soon.

More Info about this drug. It's to treat acute hearing loss (if it is severe) and it's taken orally. Sensorion is a spinoff INSERM, which is also Partner of Affichem Pharma, so maybe it's their AF243 drug, but this is just speculation. I wrote Affichem several times and never got answer...

I was surprised to read that there is a placebo group in animal studies.

What about: Sensorion REGAIN Consortium Novartis Decibel Therapeutics Otomagnetics There are many more as well. These are all companies looking to restore hearing loss. We still don’t know what the outcome will be regarding tinnitus, and all I’m saying is it would be wise to wait and...

Sensorion: Acute Regain: Sucks compared to fx322 Novartis: Works, sucks compared to fx322. Decibel: They have not announced anything except a prophylactic Otomagnetic: Just a delivery method. The reason I say the other 2 suck is because they are just focused on growing hair cells. Fx322 does...

Cure is a strong word. I think enough has been discovered already about healing the ear that they probably all have something going on that will be effective to restore hearing, and at the very least reduce tinnitus.

Thank you Aurelian, Not sure this was clear before: ".... Clinical trial planning is ongoing and Sensorion intends to initiate a phase 2 study with SENS-401 in this indication during the first half of 2018." So we have a third trial planned in 2018 for hearing loss. I'm very curious how...

Hi, Sensorion Selects New Drug Candidate to Treat Vestibular and Auditory Disorders Associated with Inner Ear Lesions : SENS-401 (September 29th, 2016) Download press release (EN) Download press release (FR)

some more info http://www.sensorion-pharma.com/fr/notre-expertise-technologique/congres-abstracts http://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=201049094

Sorry, I had not seen that one the conversation dedicated for Sensorion. I am curious also. Apparently, it would be compressed(restrained) to set during 28 days, but it seems to me "too easy" to get back the hearing after a month. i have T since 4 years and H since 1 year but I am sure that 2018...

Out of Frequency Therapeutics, Decibel Therapeutics, Sensorion and Otonomy which one do you believe will actually cure tinnitus?

Damn did you see this? "The procedure involves going down the ear canal and detaching the tympanic membrane (ear drum) to reach the cochlea. A laser is used to create a hole in the cochlea to deliver the CGF166. Remarkably, it only takes 30 minutes and the patient is sent home the same day."...

Isn't it only for acute hearing loss (sudden sensorineural hearing loss (SSNHL))? SENS-401, the Company’s drug candidate being developed for the treatment of acute sensorineural hearing loss A first-in-class drug to treat Sudden SensoriNeural Hearing Loss (SSNHL). To protect against inner...

...animal tests:puppykisses: Yes the cochlea is more difficult to reach, but this morning I read a document where drugs past the blood brain barrier that protects the cochlea...

Sensorion will be presenting some preclinical results at the American Neurotology Spring meetings: http://www.sensorion-pharma.com/images/press_release/20180409-PR-EN-ANS-COSM_Curtain_Raiser-VF.pdf Title of the presentation is "The Clinical Stage Otoprotectant SENS-401 Effectively Reduces...

...in signs of vestibular dysfunction (nystagmus, vertigo and loss of balance) and recovery/preservation of patient independence." (http://www.sensorion-pharma.com/en/sens218) This suggests the target of may be vestibular issues rather than hearing. Their initial candidate (SENS-111) is for...

Yes, Sensorion was a start-up here too. I don't know how it works on clinicaltrials.gov but the study isn't up to date and is completed. They didn't publish the results as of yet but Zeta Technologies did a presentation about it in September. I think I will post more about it in your thread...

...of hearing loss. Regeneron acquired DB-OTO as part of its $109 million acquisition of Decibel Therapeutics last year. Meanwhile, French biotech Sensorion is running a phase 1/2 trial of its SENS-501 (OTOF-GT) candidate and has a candidate for GJB2-related hearing loss in preclinical development.

...fight age related hearing loss. Also Roche has something under the hood with it's Inception 3 project, but there is not a lot of info. The same for Affichem in the Tinnitus field there are still AudioCure and Sensorion... So many companies with the same goal finding a working inner ear...

While it’s not of scanning electron microscope quality, Sensorion has a picture on their site that shows even after widespread damage, the hair cells regenerated from their drug realign properly. You could email them to ask about whether or not everything including the bundles are oriented...

Very Very Exciting!

...- FX-322 - Phase 2 Genvec / Novartis Audion - Regain Other Trials 2018 Xenon Pharma - XEN-1101 (new retigabine / for epilepsy) - Phase 2 Sensorion - Sens-401 (for SSNHL) - Phase 2 University of Michigan - device (reduce tinnitus) Trials supposed to begin in 2019 Otonomy - OTO-313...

...loss and tinnitus Audion Therapeutics (Netherlands) Audio Cure (Germany) Acousia Therapeutics (Germany) Böhringer Ingelheim (Germany) Sensorion Pharma (France) Soundpharmaceuticals (USA) Decibel Therapeutics (USA) Frequency Therapeutics (USA) Otologic Pharma (Oklahoma USA) Affichem SA...

Thank you

...we just need a company with the first causal treatment for inner ear diseases. And many are on the start: -Auris Medical -Otonomy -Sensorion -AudioCure -Audion-tx -Decibel-tx -Frequency-tx -Novartis (cgf-166) -Roche (Inception3) -Sound Pharmaceuticals -Quark Pharmaceuticals -Affichem...

You are being very black and white. You can’t say it’s the only one when there are other companies out there trying to restore lost hearing. You are spreading misinformation and artificially raising people’s expectations before we even know anything about its effect on tinnitus. It’s cool to be...

The problem is that most of these companies are not even in phase I... some aren't even in preclinical.

Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN), a biotech company specializing in the treatment of inner ear diseases, today announces new data presented in multiple poster presentations at the Association for Research in Otolaryngology’s (ARO) 41st Annual MidWinter Meeting in San Diego...

With so much activity going on it would seem like a good bet that we will have answer about tinnitus relatively soon.

From the Audion trial page "if you also suffer from tinnitus, and this is more of a problem to you than your hearing loss, you will not be eligible to take part." *farts* WHY? :bored:

This makes me angry. However many of the participants are likely elderly so it makes sense... I feel as if the FDA has become a personal enemy of mine: Not only do their policies keep medicine from being exchanged between two consenting adult parties (buyer and seller), but they have forbidden...